Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Authors:

Abstract
No abstract available
Funding Information
  • Eli Lilly and Company

This publication has 20 references indexed in Scilit: